Lu Yang

About Lu Yang
  • Growing evidence points to a link between inflammation and the initiation of prostate cancer. It is also linked to the progression of prostate cancer to being resistant to treatment.
  • Dr. Yang and his team will conduct four Phase 1 clinical studies to investigate the effects of anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs), like aspirin, on prostate tumor initiation and progression.
  • His team will also outline the precise molecular mechanism behind the effects of anti-inflammatory agents on preventing disease progression.

What this means to patients: The use of non-steroidal, anti-inflamatory drugs may provide a new treatment to prevent prostate cancer initiation and progression.

Award

2013 PCF China Young Investigator in Honor of Stanley Zax

Lu Yang, MD

West China Hospital, Sichuan University

Mentors:

Qiang Wei, MD and Tianyong Fan, MD

Project Title:

Treating inflammation to prevent prostate cancer initiation and progression.